Methotrexate and rheumatoid arthritis associated interstitial lung disease
Pierre-Antoine Juge,Joyce S. Lee,Jessica Lau,Leticia Kawano-Dourado,Jorge Rojas Serrano,Marco Sebastiani,Gouri Koduri,Eric Matteson,Karina Bonfiglioli,Marcio Sawamura,Ronaldo Kairalla,Lorenzo Cavagna,Emanuele Bozzalla Cassione,Andreina Manfredi,Mayra Mejia,Pedro Rodríguez-Henriquez,Montserrat I. González-Pérez,Ramcés Falfán-Valencia,Ivette Buendia-Roldán,Gloria Pérez-Rubio,Esther Ebstein,Steven Gazal,Raphaël Borie,Sébastien Ottaviani,Caroline Kannengiesser,Benoît Wallaert,Yurdagul Uzunhan,Hilario Nunes,Dominique Valeyre,Nathalie Saidenberg-Kermanac'h,Marie-Christophe Boissier,Lidwine Wemeau-Stervinou,René-Marc Flipo,Sylvain Marchand-Adam,Pascal Richette,Yannick Allanore,Claire Dromer,Marie-Elise Truchetet,Christophe Richez,Thierry Schaeverbeke,Huguette Lioté,Gabriel Thabut,Kevin D. Deane,Joshua J. Solomon,Tracy Doyle,Jay H. Ryu,Ivan Rosas,V. Michael Holers,Catherine Boileau,Marie-Pierre Debray,Raphaël Porcher,David A. Schwartz,Robert Vassallo,Bruno Crestani,Philippe Dieudé
DOI: https://doi.org/10.1183/13993003.00337-2020
IF: 24.3
2020-07-09
European Respiratory Journal
Abstract:Question addressed by the study Methotrexate (MTX) is a key anchor drug for rheumatoid arthritis (RA) management. Fibrotic interstitial lung disease (ILD) is a common complication of RA. Whether MTX exposure increases the risk of ILD in patients with RA is disputed. We aimed to evaluate the association of prior MTX use with development of RA-ILD. Methods Through a case–control study design with discovery and international replication samples, we examined the association of MTX exposure with ILD in 410 patients with chronic fibrotic ILD associated with RA (RA-ILD) and 673 patients with RA without ILD. Estimates were pooled over the different samples using meta-analysis techniques. Results Analysis of the discovery sample revealed an inverse relationship between MTX exposure and RA-ILD (adjusted OR 0.46, 95% CI 0.24–0.90; p=0.022), which was confirmed in the replication samples (pooled adjusted OR 0.39, 95% CI 0.19–0.79; p=0.009). The combined estimate using both the derivation and validation samples revealed an adjusted OR of 0.43 (95% CI 0.26–0.69; p=0.0006). MTX ever-users were less frequent among patients with RA-ILD compared to those without ILD, irrespective of chest high-resolution computed tomography pattern. In patients with RA-ILD, ILD detection was significantly delayed in MTX ever-users compared to never-users (11.4±10.4 years and 4.0±7.4 years, respectively; p<0.001). Answer to the question Our results suggest that MTX use is not associated with an increased risk of RA-ILD in patients with RA, and that ILD was detected later in MTX-treated patients.
respiratory system